Industry stakeholders can take steps to better understand the needs and preferences of GLP-1 patients who seek to address one—and often multiple—aesthetic concerns.The rapid adoption of glucagon-like peptide-1 (GLP-1) agonists is changing the life sciences landscape, with ripple effects extending well beyond cardiometabolic and obesity care. Global prescriptions of GLP-1 agonist therapies grew at a […]
